Skip to Main Content

As frustration mounts over the slower-than-expected uptake of biosimilars in the marketplace, two U.S. federal agencies vowed to take steps to ensure that companies seeking to sell these medicines have a chance to compete for U.S. patients.

In a joint statement, the Food and Drug Administration and the Federal Trade Commission cited several issues that are believed to have impeded wider use of biosimilars, which are lower-priced variants of brand-name biologics that are expected to deliver the same health outcomes.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!